The Chemours Company (NYSE:CC) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of The Chemours Company (NYSE:CC) have been assigned an average rating of “Hold” from the eight analysts that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $24.88.

Several research analysts have weighed in on the stock. Morgan Stanley lowered their price objective on shares of Chemours from $30.00 to $25.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 5th. UBS Group decreased their price target on Chemours from $30.00 to $28.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. The Goldman Sachs Group reduced their target price on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating for the company in a research note on Tuesday, September 3rd. JPMorgan Chase & Co. cut their price target on shares of Chemours from $25.00 to $18.00 and set a “neutral” rating on the stock in a report on Tuesday, August 6th. Finally, Barclays upped their price objective on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th.

Insider Transactions at Chemours

In related news, SVP Alvenia Scarborough sold 7,500 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the sale, the senior vice president now directly owns 16,645 shares in the company, valued at approximately $343,552.80. The trade was a 31.06 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.47% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CC. M&T Bank Corp lifted its position in shares of Chemours by 4.1% during the third quarter. M&T Bank Corp now owns 510,343 shares of the specialty chemicals company’s stock worth $10,370,000 after acquiring an additional 20,122 shares in the last quarter. Barclays PLC raised its stake in shares of Chemours by 28.4% during the 3rd quarter. Barclays PLC now owns 107,549 shares of the specialty chemicals company’s stock valued at $2,185,000 after purchasing an additional 23,766 shares during the period. Vision One Management Partners LP purchased a new stake in Chemours during the 3rd quarter worth about $28,252,000. Two Sigma Advisers LP boosted its stake in Chemours by 9.4% in the 3rd quarter. Two Sigma Advisers LP now owns 503,100 shares of the specialty chemicals company’s stock worth $10,223,000 after purchasing an additional 43,200 shares during the period. Finally, RBF Capital LLC grew its holdings in Chemours by 42.8% during the 3rd quarter. RBF Capital LLC now owns 414,618 shares of the specialty chemicals company’s stock valued at $8,425,000 after buying an additional 124,311 shares in the last quarter. 76.26% of the stock is owned by institutional investors.

Chemours Price Performance

Chemours stock opened at $18.88 on Friday. The stock has a market capitalization of $2.82 billion, a price-to-earnings ratio of 37.76 and a beta of 1.75. Chemours has a 52-week low of $15.10 and a 52-week high of $32.70. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The stock’s 50 day moving average price is $19.12 and its two-hundred day moving average price is $21.80.

Chemours (NYSE:CC) last issued its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. During the same period in the prior year, the firm earned $0.64 earnings per share. Chemours’s revenue was up .9% on a year-over-year basis. On average, equities analysts predict that Chemours will post 1.35 earnings per share for the current year.

Chemours Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Friday, November 15th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 5.30%. The ex-dividend date is Friday, November 15th. Chemours’s payout ratio is 200.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.